How have ETX shares performed in 2024?

e-therapeutics' stock was trading at GBX 8.24 on January 1st, 2024. Since then, ETX stock has increased by 20.8% and is now trading at GBX 9.95. View the best growth stocks for 2024 here .

How were e-therapeutics' earnings last quarter?

e-therapeutics plc (LON:ETX) announced its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.03.

What other stocks do shareholders of e-therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR) , Sound Energy (SOU) , 4D pharma (DDDD) , Chicken Soup for the Soul Entertainment (CSSE) , Crescent Point Energy (CPG) , Collagen Solutions plc (COS.L) (COS) , BP (BP) , Bushveld Minerals (BMN) and Alstom (ALSMY) .

How do I buy shares of e-therapeutics?

Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:ETX

e-therapeutics (ETX) Share Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free ETX Stock Alerts

GBX 9.95

-0.25 (-2.45%)

(As of 04/18/2024 ET)

Compare

Today's Range: 9.60
▼
10.20
50-Day Range: 9.55
▼
16.55
52-Week Range: 8
▼
24

Volume: 1.07 million shs
Average Volume: 548,226 shs
Market Capitalization: £58.14 million

P/E Ratio: N/A
Dividend Yield: 3.35%
Price Target: N/A

Stock Analysis Chart Competitors Headlines Insider Trades

Get e-therapeutics alerts:

Ad American Alternative

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

About e-therapeutics Stock (LON:ETX)

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

ETX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ETX Stock News Headlines

April 18, 2024 | americanbankingnews.com

e-therapeutics (LON:ETX) Shares Cross Below 200-Day Moving Average of $11.94

April 11, 2024 | msn.com

Eliem Therapeutics to buy Tenet, announces $120 million private placement

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | seekingalpha.com

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

April 10, 2024 | lse.co.uk

e-Therapeutics says company faces lack of interest as UK listing

April 10, 2024 | marketwatch.com

e-Therapeutics Shares Fall on London Delisting Plan; Mulls Move to New York

April 10, 2024 | msn.com

‘Lack of appetite’ in London drives another high-tech firm to Nasdaq

April 10, 2024 | msn.com

Drug discovery firm e-therapeutics to quit London Stock Exchange following £29m fundraise

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 16, 2024 | msn.com

Aquestive maps out FDA approval for sublingual anaphylaxis drug

January 3, 2024 | finance.yahoo.com

We're Hopeful That e-therapeutics (LON:ETX) Will Use Its Cash Wisely

December 27, 2023 | msn.com

Medical innovator e-therapeutics to stop trading on US-based market

November 13, 2023 | markets.businessinsider.com

Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery

October 30, 2023 | businesswire.com

Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich

October 26, 2023 | proactiveinvestors.com

E-therapeutics bolsters generative AI integration and strategic...

September 28, 2023 | benzinga.com

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

September 28, 2023 | marketwatch.com

Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold

September 20, 2023 | proactiveinvestors.com

e-therapeutics appoints new CFO

July 13, 2023 | uk.finance.yahoo.com

ETX.L - e-Therapeutics plc

June 8, 2023 | wsj.com

Elicio Therapeutics Inc.

May 23, 2023 | businesswire.com

AgeX Therapeutics Announces Appeal of NYSE American Determination

May 10, 2023 | businesswire.com

Rapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian Market

May 10, 2023 | marketwatch.com

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

May 6, 2023 | marketwatch.com

Acute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,Pfizer

May 4, 2023 | marketwatch.com

E-Therapeutics FY 2023 Pretax Loss Widened on Higher R&D Costs

May 4, 2023 | finance.yahoo.com

e-Therapeutics working to capitalise on AI "blindside"

April 28, 2023 | markets.businessinsider.com

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

See More Headlines

Receive ETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/17/2020
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:ETX
CUSIP: N/A
CIK: N/A
Web: www.etherapeutics.co.uk
Phone: +44-1993-880000
Fax: N/A
Employees: 34
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-10,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -38.75%
Return on Assets: -29.10%

Debt

Debt-to-Equity Ratio: 0.33
Current Ratio: 22.20
Quick Ratio: 20.13

Sales & Book Value

Annual Sales: £295,000.00
Price / Sales: 197.09
Cash Flow: GBX 1.96 per share
Price / Cash Flow: 5.07
Book Value: GBX 5 per share
Price / Book: 1.99

Miscellaneous

Outstanding Shares: 584,330,000
Free Float: N/A
Market Cap: £58.14 million
Optionable: Not Optionable
Beta: 0.48

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Ahmad Ali Mortazavi (Age 53)
CEO & Director
Comp: $270k
Mr. Timothy Bretherton
CFO, Director of Finance & Operations and Company Secretary
Dr. Laura Roca-Alonso Ph.D.
Chief Operating & Business Officer
Mr. Alan Whitmore B.Sc.
Ph.D., Chief Scientific Officer
Mr. Ankit Sharma
Head of Software Engineering
Mr. Graham Craggs
Head of Therapeutic Discovery

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ETX Stock Analysis - Frequently Asked Questions

How have ETX shares performed in 2024?: e-therapeutics' stock was trading at GBX 8.24 on January 1st, 2024. Since then, ETX stock has increased by 20.8% and is now trading at GBX 9.95.
View the best growth stocks for 2024 here.
How were e-therapeutics' earnings last quarter?: e-therapeutics plc (LON:ETX) announced its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.03.
What other stocks do shareholders of e-therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY).
How do I buy shares of e-therapeutics?: Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ETX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial